U.S. Capitol with U.S flag
Expect the 340B program to be get signficant attention at the federal and state level this year, 340B Report Publisher and CEO Ted Slafsky says.

340B REPORT SPONSOR SPOTLIGHT

340B Report Publisher and CEO Slafsky: Three 340B Observations for 2023

In his inaugural column for Verity Solutions, 340B Report Publisher and CEO Ted Slafsky offers insights “on what to expect in Washington, D.C., and the states in 2023 when it comes to the 340B program.”

Slafsky in the column makes three key observations:

  • Don’t expect major healthcare legislation to pass in new Congress. “Major health care legislation and drug pricing bills have little or no chance of getting enacted in the next two years,” Slafsky predicts.
  • Expect attention to the 340B program to heat up in both chambers. “We can expect Congressional attention to the 340B program to heat up quickly now that the GOP has retaken the House,” he says.
  • Arkansas’s unique 2021 law to protect 340B contract pharmacy arrangements could be a model for other states. “As the battle between the federal government and pharmaceutical manufacturers over the permissibility of restrictions on the use of the 340B discounts in the contract pharmacy setting reaches its third year, don’t be surprised to see more states trying to take matters in their own hands,” Slafsky says.

You can read the entire article here.

Editor at Large | Website | + posts
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report